Xvivo Perfusion Ab · OMXSTO:XVIVO
Xvivo Perfusion Ab — Q2 2026 Earnings Presentation
22 slides from Xvivo Perfusion Ab's earnings presentation, Jul 14, 2026
Slide 1: Interim report Q2 2026
Interim report Q2 2026 Earnings call, July 14, 2026 XVIVO Perfusion AB (publ) Kim Castellano Heart transplant recipient, US
Slide 2: Today’s presenters
Today’s presenters Christoffer Kristoffer Rosenblad Nordström CEO CFO 2 DOC ID: Interim report Apr-Jun 2026
Slide 3: Q2 Financials – at a glance
Q2 Financials – at a glance Organic growth, local currencies Net Sales Thoracic Net sales SEK 239 Million Net Sales SEK 158 million +53%** Gross margin 83% Sales growth Organic Abdominal Net sales growth +36%* Net Sales SEK 65 million Gross margin 57% +26% - Currency effect -2% - Total growth 34% Se
Slide 4: YTD Financials – at a glance
YTD Financials – at a glance Organic growth, local currencies Net Sales Thoracic Net sales SEK 480 Million Net Sales SEK 318 million +38%** Gross margin 83% Sales growth Organic Abdominal Net sales growth +29%* Net Sales SEK 131 million Gross margin 55% +25% - Currency effect -8% - Total growth 21%
Slide 5: Q2 highlights & Key message
Q2 highlights & Key messsage Alex Moroianu Heart transplant recipient, AU 5 DOC ID: Interim report Apr-Jun 2026
Slide 6: Commercial momentum continues
Commercial momentum continues Focused execution driving growth across all major organ areas Strong Q2 momentum continued from Q1 1 Increasing adoption of XVIVO’s technologies reinforces confidence in long-term growth opportunities EVLP adoption continues 2 Expanding beyond the largest customer base,
Slide 7: Scaling and investing for growth
Scaling and investing for growth … while maintaining profitability and solid cashflow Focus on scale-up and go-to-market 5 Future growth and product launches to be supported by further investments into commercial capabilities, QA/RA and Operations Progress in heart regulatory processes 6 European CE
Slide 8: Regulatory update
Regulatory update 8 DOC ID: Interim report Apr-Jun 2026
Slide 9: Clinical Trial Status & Tentative Timeline
Clinical Trial Status & Tentative Timeline REVIEW & PRECLINICAL CLINICAL MARKET APPROVAL FOLLOW-UP • Patient enrolment completed May 2023 • 204 patients included across 15 centers 12-month 12-month patient Commercial launch pending across 8 countries patient follow-up completed CE-mark*. Currently s
Slide 10: Liver Assist in the US
Liver Assist in the US Status update • All regulatory approvals obtained to initiate the PMA study • Trial activities temporarily paused to evaluate faster and more cost-efficient regulatory pathways • First HOPE DeNovo liver perfusion now FDA-approved • Over the summer – start preparing for filing
Slide 11: Financial Performance Q2
Financial Performance Q2 11 DOC ID: Interim report Apr-Jun 2026
Slide 12: Net sales and key ratios
Net sales and key ratios Apr-Jun Apr-Jun YTD YTD Full Year SEK Million 2026 2025 2026 2025 2025 Net sales 239 178 480 396 812 Sales growth, % +34 % -15 % 21 % 0% -1 % - Organic growth*, % +36 % -9% +29 % +1 % +3 % - Organic growth* excluding trial revenue, % +36 % -3 % +26 % +8 % +8 % Gross profit 1
Slide 13: Thoracic – Q2 Highlights
Thoracic – Q2 Highlights Net sales by Net sales by Net sales by organ Net Sales region product category 158 MSEK (105) 1% 15% Organic growth +53 % (-19) 33% 33% Organic growth (excl. heart trial revenue) 59% 66% +52 % (-13) 85% 8% Gross margin 83 % (86) Lung Heart Americas APAC Machine perfusion Sta
Slide 14: Abdominal – Q2 Highlights
Abdominal – Q2 Highlights Net sales by Net Sales Net sales by organ region 65 MSEK (52) 12% Organic growth 5% 26 % (19) 34% Gross margin 66% 57 % (68) 83% Liver Kidney Americas APAC EMEA Liver sales Kidney sales Q2 43 MSEK (38) 22 MSEK (14) +11% +72% 14 DOC ID: Interim report Apr-Jun 2026
Slide 15: Services – Q2 Highlights
Services –Q2 Highlights Net Sales Net sales by service 2026 focus: 15 MSEK (21) • Return to growth – leveraging Organ Recovery strengthened surgical capacity, NRP Organic growth service offering and EVLP momentum 26% -25 % (-19) • Preparations for US heart launch Gross margin 10 % (34) 74% 2026 focu
Slide 16: EBITDA
EBITDA Q2 2026 EBITDA (adj), by quarter EBITDA (adj), R12 months SEKm SEKm • XVIVOs scalable business model combined with strong gross margins provides a solid 40% 250 40% foundation for increasing profitability over time 70 225 35% 35% • Investments will be directed to sales and 60 56 200 188 188 c
Slide 17: Cashflow and financial position
Cashflow and financial position Cash flow from Cashflow from Q2 Cashflow operating activities (R12) R12 investing activities • Cash flow from operating +237m SEKm Q2 Q2 YTD YTD activities SEK +63 million (9) 300 SEKm 2026 2025 2026 2025 • Investments SEK -68 million (-72) 275 237 Total cashflow 250
Slide 18: Outlook
Outlook Alex Moroianu Heart transplant recipient, AU 18
Slide 19: XVIVO is changing the future of organ transplantation
XVIVO is changing the future of organ transplantion Focus 2026 • Drive continued EVLP adoption in the US by leveraging centralized perfusion service models • Continue grow adoption of Flowhawk and strengthen Organ recovery customer base in the US • Further develop our European leadership in liver pe
Slide 20: Long term outlook
Long term outlook • The demand for transplants are x 10 of today’s supply • Sales value of machine perfusion vs cold static storage is ~x 10 • Machine perfusion and service models have proven to increase the number of organs used for transplantation • XVIVO has unique, innovative and world leading p
Slide 21: Nobody should die waiting for a new organ
Nobody should die waiting for a new organ Fredrica Höglund Liver transplant recipient, Sweden 21 DOC ID: Interim report Apr-Jun 2026
Slide 22: Financial calendar & contacts
Financial calendar & contacts Financial reports 2026/2027 Investor Relations Interim report July – September 2026: October 22, 2026 Christoffer Rosenblad, CEO Telephone: +46 735 19 21 59 Year-end report 2026: January 28, 2027 E-mail: christoffer.rosenblad@xvivogroup.com Interim report January – Marc